Patients with CKD have a 56% higher prevalence of severe mental health disorders such as schizophrenia, bipolar disorder, or ...
The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...
Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney disease — ischemic benefits not observed in trials of selective SGLT2 inhibitors.
New University of Dundee research has revealed that using artificial intelligence (AI) to analyse photos taken during routine ...
A comprehensive study published in the journal of BMJ Rheumatic & Musculoskeletal Diseases focused on the prevalence and risk ...
Explore the efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney ...
Presentation of full results from Phase 2 AURORA and BEACON studies at 2024 ASH Annual Meeting demonstrating significant ...
Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
Medtronic, a leader in medical technology and Philips, a leader in health technology announced the signing of a Memorandum of ...
The excess payments Medicare Advantage plans receive for higher risk scores may be more influenced by differences in coding practices rather than actual differences in disease burden between MA and ...
Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results